Orencia

Rheumatoid Arthritis

Orencia is used in adults to reduce the signs and symptoms of moderate to severe rheumatoid arthritis. It may help slow the progression of joint damage and improve physical function. It can be used alone or with other medications, though it is typically not used with other biologic drugs.

Psoriatic Arthritis

In adults, this medication is used to treat active psoriatic arthritis, a condition that causes joint pain and swelling along with skin psoriasis.

Juvenile Idiopathic Arthritis

Orencia is approved for children 2 years of age and older who have moderate to severe polyarticular juvenile idiopathic arthritis. This condition involves inflammation in multiple joints.

Graft-Versus-Host Disease Prevention

This medication is also used in adults and children 2 years of age and older to help prevent acute graft-versus-host disease (aGVHD). This is a serious condition where transplanted stem cells attack the recipient's body. It is specifically used for patients receiving a hematopoietic stem cell transplant from an unrelated donor.

Targeting the Immune System

Orencia belongs to a class of medications known as selective costimulation modulators. It is designed to interfere with the process that triggers inflammation in the body. In conditions like rheumatoid arthritis and psoriatic arthritis, the immune system mistakenly attacks healthy joints and tissues.

How T-Cells Are Affected

The medication specifically targets T-cells, which are a type of white blood cell involved in the body's immune response. For a T-cell to become fully active and cause inflammation, it usually requires two separate signals from other cells. Orencia works by:

• Binding to specific proteins on the surface of cells that communicate with T-cells.
• Blocking the second signal necessary for T-cell activation.
• Preventing the T-cells from sending out chemical messages that lead to pain and swelling.

By keeping these T-cells in an inactive state, Orencia helps to lower the overall inflammatory response. This can lead to a reduction in symptoms and may help slow down the progression of joint damage over time.

Common Side Effects

Many people using Orencia experience mild side effects. These may include:

• Headache
• Nausea
• Sore throat or cough
• Dizziness
• Back pain
• Redness, swelling, or itching at the injection site

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of infection: Fever, chills, night sweats, persistent cough, or feeling very tired.
• Allergic reactions: Hives, swelling of the face, lips, or throat, and difficulty breathing.
• Respiratory issues: Increased shortness of breath or worsening of chronic obstructive pulmonary disease (COPD) symptoms.
• Skin changes: New skin growths or changes in the appearance of existing moles.

Some people may experience a reaction during or shortly after receiving an intravenous infusion, such as dizziness, headache, or changes in blood pressure.

Serious Infections

Orencia affects the immune system, which may decrease the body's ability to fight infections. Some people have developed serious infections while taking this medication, including pneumonia, skin infections, and urinary tract infections. Healthcare providers typically screen for tuberculosis (TB) and viral hepatitis before treatment begins. If a serious infection develops during treatment, the medication is usually stopped until the infection is under control.

Allergic Reactions

Serious allergic reactions, including anaphylaxis, can occur during or after the administration of Orencia. Symptoms may include hives, swelling of the face or throat, and difficulty breathing. Emergency medical help is necessary if these symptoms appear.

Respiratory Issues in COPD

People with chronic obstructive pulmonary disease (COPD) may experience more frequent respiratory problems while using Orencia. These can include coughing, shortness of breath, or worsening of COPD symptoms.

Vaccinations

Live vaccines should not be administered while taking Orencia or for at least three months after the last dose. The medication may also reduce the effectiveness of other types of vaccines.

Use with Other Biologics

Combining Orencia with other biologic medications, such as TNF antagonists or anakinra, is generally not recommended. Using these drugs together can significantly increase the risk of serious infections.

Malignancy Risk

The impact of Orencia on the development of cancer is not fully known. However, medications that suppress the immune system may potentially increase the risk of certain types of malignancies.

Monitoring for GVHD Prevention

When used to prevent acute graft-versus-host disease, patients should be monitored for the reactivation of viruses such as Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). Preventive treatments for these viruses are often started alongside Orencia.

Pregnancy

It is not currently known if Orencia can cause harm to an unborn baby. While animal studies did not show a high risk of birth defects, they did show some changes in the immune systems of offspring exposed to high doses. Because this medication is known to cross the placenta, it may affect the immune system of a developing fetus.

If you are pregnant or planning to become pregnant, discuss the potential risks and benefits with your healthcare provider. There is a pregnancy registry available for women who take Orencia during pregnancy to monitor the health of both the mother and the baby. This registry helps researchers understand the effects of the medication on pregnancy outcomes.

Breastfeeding

It is not known whether Orencia passes into human breast milk or how it might affect a nursing infant. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in nursing infants, a decision should be made whether to stop nursing or stop the medication, taking into account the importance of the drug to the mother's health.

Healthcare providers typically recommend discussing all options for infant feeding if you require treatment with this medication.

Intravenous Infusion

Orencia is supplied as a sterile, preservative-free lyophilized powder in a single-dose vial. This form must be reconstituted and diluted by a healthcare professional before being administered as an intravenous infusion.

Subcutaneous Injection

Orencia is also available as a solution for subcutaneous injection. It is provided in the following delivery systems:

• Prefilled Syringe: A single-dose glass syringe equipped with a needle guard. It is available in different strengths to accommodate pediatric and adult dosing.
• ClickJect Autoinjector: A single-dose, disposable autoinjector designed for use in adults.

The solution for injection is clear to slightly opalescent and colorless to pale yellow.

FDA Approval and Indications

Orencia was first approved by the U.S. Food and Drug Administration (FDA) in 2005. It is currently approved for the following uses:

• Adult Rheumatoid Arthritis: For reducing signs and symptoms and slowing the progression of structural damage in adults with moderately to severely active rheumatoid arthritis.
• Polyarticular Juvenile Idiopathic Arthritis: For patients 2 years of age and older with moderately to severely active disease.
• Psoriatic Arthritis: For adults with active psoriatic arthritis.
• Graft-Versus-Host Disease (GVHD) Prevention: For adults and children 2 years of age and older undergoing hematopoietic stem cell transplantation from an unrelated donor, used in combination with other immunosuppressants.

Regulatory Milestones

In December 2021, the FDA expanded Orencia's approval to include the prevention of acute graft-versus-host disease. This was a significant regulatory milestone as it was the first drug approved by the FDA for this specific indication. The approval was based on clinical data showing improved survival and reduced risk of severe GVHD in patients receiving the medication alongside standard care.

Safety Oversight

Orencia does not currently have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. However, the FDA requires specific screening and monitoring for patients using this medication. This includes testing for latent tuberculosis and viral hepatitis before starting treatment, as the drug's effect on the immune system may increase the risk of serious infections. The FDA continues to monitor post-marketing reports regarding the long-term safety profile of the drug, including potential risks of malignancies and severe hypersensitivity reactions.

Cost Considerations

Orencia is a biologic medication, and its price can be significant. The actual amount a patient pays depends on several factors:

• Formulation: The medication is available as a prefilled syringe or autoinjector for subcutaneous use, and as a powder for intravenous infusion. Subcutaneous versions are often used at home, while infusions require a clinical setting, which may add to the overall cost.
• Insurance Type: Coverage varies between private insurance, Medicare, and Medicaid. Medicare Part B typically covers infusions administered in a doctor's office, while Part D usually covers the subcutaneous version.
• Pharmacy Choice: Specialty pharmacies are often required to dispense biologic medications like Orencia.

Financial Support

Financial assistance may be available through the manufacturer for patients who meet certain eligibility criteria. This can include copay assistance for those with commercial insurance or patient assistance programs for those without adequate coverage. It is recommended to check with the insurance provider and the manufacturer to determine the most accurate out-of-pocket costs.